Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-28T06:30:23.773Z Has data issue: false hasContentIssue false
  • English
  • Français

mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months

Part of: SARS-CoV-2/COVID-19

Published online by Cambridge University Press:  06 September 2021

Aaron J. Tande Open the ORCID record for Aaron J. Tande [Opens in a new window] ,
Benjamin D. Pollock ,
Nilay D. Shah ,
Matthew Binnicker  and
Elie F. Berbari Open the ORCID record for Elie F. Berbari [Opens in a new window]
Aaron J. Tande*
Affiliation:
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota
Benjamin D. Pollock
Affiliation:
Department of Quality, Experience, and Affordability, Mayo Clinic, Rochester, Minnesota Division of Health Care Delivery Research, Robert D. and Patricia E, Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota
Nilay D. Shah
Affiliation:
Delta Air Lines, Atlanta, Georgia
Matthew Binnicker
Affiliation:
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
Elie F. Berbari*
Affiliation:
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota
*
Author for correspondence: Aaron J. Tande, E-mail: [email protected]. Or Elie F. Berbari, E-mail: [email protected]
Author for correspondence: Aaron J. Tande, E-mail: [email protected]. Or Elie F. Berbari, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Research Brief
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 3 , March 2022 , pp. 393 - 395
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

a

Authors of equal contribution.

References

Swift, MD, Breeher, LE, Tande, AJ, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis 2021. doi: 10.1093/cid/ciab361.Google Scholar
Abu-Raddad, LJ, Chemaitelly, H, Butt, AA, National study group for C-V. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021;385:187–189.Google Scholar
Tande, AJ, Pollock, BD, Shah, ND, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening. Clin Infect Dis 2021. doi: 10.1093/cid/ciab229.Google Scholar
Tang, L, Hijano, DR, Gaur, AH, et al. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA 2021;325:2500–2502.Google Scholar
Haas, EJ, Angulo, FJ, McLaughlin, JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819–1829.Google ScholarPubMed
CDC COVID data tracker variant proportions. Centers for Disease Control and Prevention website. https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Published 2021. Accessed June 10, 2021.Google Scholar